| scholarly article | Q13442814 |
| P2093 | author name string | Chi Chiu Mok | |
| Chak Sing Lau | |||
| Kwok Wah Chan | |||
| Carmen Tze Kwan Ho | |||
| Raymond Woon Sing Wong | |||
| P2860 | cites work | Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression | Q28372716 |
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population | Q33332503 | ||
| The prognosis of lupus nephritis in African-Americans: a retrospective analysis | Q33491801 | ||
| Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis | Q34244145 | ||
| Outcome of the acute glomerular injury in proliferative lupus nephritis | Q35814458 | ||
| Prognostic factors in lupus nephritis. Contribution of renal histologic data | Q36600287 | ||
| Treatment of Diffuse Proliferative Lupus Nephritis with Prednisone and Combined Prednisone and Cyclophosphamide | Q40691464 | ||
| The course and treatment of lupus nephritis | Q40759736 | ||
| Treatment of lupus nephritis: a meta-analysis of clinical trials | Q40906582 | ||
| Prognosis and treatment of systemic lupus erythematosus. | Q41241399 | ||
| Therapy with pulse methylprednisolone and short course pulse cyclophosphamide for diffuse proliferative glomerulonephritis | Q43599863 | ||
| Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens | Q43691810 | ||
| "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. | Q50988300 | ||
| Clinical effects of intermittent, intravenous cyclophosphamide in severe systemic lupus erythematosus. | Q53994187 | ||
| Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. | Q54267030 | ||
| Intermittent intravenous cyclophosphamide therapy for lupus nephritis. | Q54352606 | ||
| Evidence for the Superiority of Immunosuppressive Drugs and Prednisone over Prednisone Alone in Lupus Nephritis | Q57244973 | ||
| Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group | Q67560104 | ||
| Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only | Q67925070 | ||
| Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs | Q68859513 | ||
| Sequential therapy for diffuse proliferative and membranous lupus nephritis: cyclophosphamide and prednisolone followed by azathioprine and prednisolone | Q70920964 | ||
| Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial | Q71553667 | ||
| Treatment of lupus glomerulonephritis with intravenous cyclophosphamide | Q72002018 | ||
| New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis | Q72345760 | ||
| Prognostic determinants in lupus nephritis: a long-term clinicopathologic study | Q72345764 | ||
| A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis | Q72702799 | ||
| Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy | Q72849010 | ||
| Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group | Q73088409 | ||
| Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network | Q73182990 | ||
| Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide | Q73322168 | ||
| Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus | Q73407589 | ||
| Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group | Q73740085 | ||
| Long-term efficacy of azathioprine treatment for proliferative lupus nephritis | Q74312793 | ||
| Mechanisms of progression of renal damage in lupus nephritis: pathogenesis of renal scarring | Q77780518 | ||
| Outcome criteria for lupus nephritis trials: a critical overview | Q77780540 | ||
| P433 | issue | 4 | |
| P921 | main subject | azathioprine | Q18939 |
| glomerulonephritis | Q605006 | ||
| P304 | page(s) | 1003-1013 | |
| P577 | publication date | 2002-04-01 | |
| P1433 | published in | Arthritis & Rheumatology | Q4797636 |
| P1476 | title | Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine | |
| P478 | volume | 46 |
| Q39418115 | A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience. |
| Q36221407 | American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis |
| Q41377503 | Anti-C1q antibody in patients with lupus nephritic flare: 18-month follow-up and a nested case-control study. |
| Q36407314 | Basic immunosuppressive drugs outside solid organ transplantation |
| Q35968394 | Challenges in bringing the bench to bedside in drug development for SLE. |
| Q87393398 | Chapter 12: Lupus nephritis |
| Q36266807 | Clinicopathological findings, treatment response and predictors of long-term outcome in a cohort of lupus nephritis patients managed according to the Euro-lupus regime: a retrospective analysis in Sri Lanka |
| Q26741266 | Current and emerging treatment options in the management of lupus |
| Q35824515 | Cyclophosphamide: new approaches for systemic lupus erythematosus |
| Q38059445 | Diagnosis and treatment of lupus nephritis flares--an update. |
| Q36462580 | Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? |
| Q44369790 | Disparities in renal replacement in lupus nephritis: current practice and future implications |
| Q50222848 | Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort |
| Q36066014 | Emergence of targeted immune therapies for systemic lupus |
| Q36634248 | Emerging drug therapies for systemic lupus erythematosus |
| Q34187282 | European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies |
| Q57689077 | Immunosuppressive treatment for proliferative lupus nephritis |
| Q35144046 | Immunotherapy for autoimmune and inflammatory renal diseases |
| Q44894708 | Intravenous cyclophosphamide--resistant systemic lupus erythematosus in Arizona |
| Q45991822 | Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? |
| Q45753606 | Long-term outcome of lupus nephritis in Asian Indians |
| Q46467090 | Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. |
| Q26740487 | Lupus Nephritis in Asia: Clinical Features and Management |
| Q36054851 | Lupus nephritis flares |
| Q35925513 | Lupus nephritis: a review of the current pharmacological treatments |
| Q38608138 | Lupus nephritis: an update |
| Q43270423 | Male gender results in more severe lupus nephritis |
| Q37754815 | Management of systemic lupus erythematosus in Chinese patients |
| Q37415711 | Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option |
| Q43677702 | Outcome of reclassification of World Health Organization (WHO) class III under International Society of Nephrology-Renal Pathology Society (ISN-RPS) classification: retrospective observational study |
| Q38123242 | Overview of lupus nephritis management guidelines and perspective from Asia |
| Q38175076 | Overview of lupus nephritis management guidelines and perspective from Asia. |
| Q85675894 | Pathological spectrums and renal prognosis of severe lupus patients with rapidly progressive glomerulonephritis |
| Q51063607 | Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis. |
| Q84145951 | Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis |
| Q35626485 | Random spot urine protein/creatinine ratio: a reliable method for monitoring lupus nephritis? |
| Q57945954 | References |
| Q41317916 | Renal flare prediction and prognosis in lupus nephritis Hispanic patients |
| Q38021183 | Role of TWEAK in lupus nephritis: a bench-to-bedside review |
| Q87705292 | Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study |
| Q44029432 | Significance of histological crescent formation in patients with diffuse proliferative lupus nephritis |
| Q41945708 | Sustained remission of lupus nephritis |
| Q38285375 | The multifaceted aspects of refractory lupus nephritis |
| Q24202572 | Treatment for lupus nephritis |
| Q24247408 | Treatment for lupus nephritis |
| Q38223302 | Treatment of lupus nephritis: practical issues in Asian countries. |
| Q44515995 | Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study |
| Q38271125 | Treatment of severe lupus nephritis: the new horizon. |
| Q35201234 | Treatment of severe proliferative lupus nephritis: the current state |
| Q35019423 | Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. |
| Q36008840 | Understanding lupus nephritis: diagnosis, management, and treatment options |
| Q37690745 | Update on emerging drug therapies for systemic lupus erythematosus |
| Q36666936 | Value of a complete or partial remission in severe lupus nephritis |
| Q34538062 | Variability of the impact of adverse events on physicians' decision making |
| Q84600171 | [Immunosuppresive treatment in patients with lupus glomerulonephritis. Review of adverse events] |
Search more.